Ascendis Pharma A/S $ASND Shares Bought by Atika Capital Management LLC

Atika Capital Management LLC grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 35.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,160 shares of the biotechnology company’s stock after buying an additional 5,760 shares during the period. Atika Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $4,406,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Jones Financial Companies Lllp boosted its position in Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the last quarter. Quadrant Capital Group LLC acquired a new stake in Ascendis Pharma A/S in the 3rd quarter valued at about $74,000. Farther Finance Advisors LLC raised its holdings in Ascendis Pharma A/S by 115.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 256 shares during the last quarter. Toth Financial Advisory Corp lifted its stake in Ascendis Pharma A/S by 33.7% in the 3rd quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 150 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Ascendis Pharma A/S by 15.2% in the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 97 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Bank of America restated a “buy” rating and issued a $262.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, March 5th. Oppenheimer boosted their price objective on Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Wedbush upped their target price on Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Wolfe Research reiterated an “outperform” rating and set a $260.00 price target on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Finally, Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $289.88.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $227.50 on Thursday. The stock has a market capitalization of $14.10 billion, a P/E ratio of -51.70 and a beta of 0.43. The firm’s 50-day moving average is $223.67 and its two-hundred day moving average is $210.73. Ascendis Pharma A/S has a 12 month low of $124.06 and a 12 month high of $248.60.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The business had revenue of $290.38 million for the quarter, compared to analyst estimates of $285.35 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.